Fulltext

Factors affecting quality of life in patients on haemodialysis: a cross-sectional study from Palestine

Zyoud SH 1 , Daraghmeh DN 2 , Mezyed DO 2 , Khdeir RL 2 , Sawafta MN 2 , Ayaseh NA 2 Show all authors , Tabeeb GH 2 , Sweileh WM 3 , Awang R 4 , Al-Jabi SW 5

Affiliations 

  • 1 Poison Control and Drug Information Center (PCDIC), College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine. saedzyoud@yahoo.com
  • 2 PharmD program, College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine
  • 3 Department of Pharmacology and Toxicology, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine
  • 4 WHO Collaborating Centre for Drug Information, National Poison Centre, Universiti Sains Malaysia (USM), Penang, 11800, Malaysia
  • 5 Department of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine
BMC Nephrol, 2016 04 27;17(1):44.
PMID: 27117687 DOI: 10.1186/s12882-016-0257-z

Abstract

BACKGROUND: Haemodialysis (HD) is a life-sustaining treatment for patients with end-stage renal disease (ESRD). HD can bring about significant impairment in health-related quality of life (HRQOL) and outcomes. Therefore, we sought to describe the patterns of HRQOL and determine the independent factors associated with poor HRQOL in Palestinian patients on HD.

METHODS: A multicenter cross-sectional study was performed from June 2014 to January 2015 using the EuroQOL-5 Dimensions instrument (EQ-5D-5L) for the assessment of HRQOL. ESRD patients undergoing HD in all dialysis centres in the West Bank of Palestine were approached and recruited for this study. Multiple linear regression was carried out to identify factors that were significantly associated with HRQOL.

RESULTS: Two hundred and sixty-seven patients were participated in the current study giving response rate of 96 %. Overall, 139 (52.1 %) were male, and the mean ± standard deviation age was 53.3 ± 16.2 years. The reported HRQOL as measured by mean EQ-5D-5L index value and Euro QOL visual analogue scale (EQ-VAS) score was 0.37 ± 0.44 and 59.38 ± 45.39, respectively. There was a moderate positive correlation between the EQ-VAS and the EQ-5D-5L index value (r = 0.42, p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications